Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –